Fujiwara Y, Takahashi Y, Okada M, Kishimoto T, et al. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. Oncologist 2022;27:e703-e722.
PMID: 35671201